



avantium

Press release

THIS PRESS RELEASE IS RESTRICTED AND IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY AND WHETHER IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR IN ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

ADVERTISEMENT. This announcement is an advertisement relating to the intention of the Company to proceed with the Offering and the admission to listing and trading of the Rights, the Offer Shares and the Additional Shares (each as defined below) (the **Admission**). This announcement does not constitute a prospectus. This announcement is for information purposes only and does not constitute, or form part of, an offer by, or invitation by or on behalf of, the Company or any representative of the Company to purchase any securities, or an offer to sell or issue, or the solicitation to buy, securities by any person in any jurisdiction where to do so would constitute a violation of the applicable laws or regulations of such jurisdiction. Further details about the Offering are included in the prospectus for the purposes of the Admission and is approved as such under the respective regulation by the Netherlands Authority for the Financial Markets (Stichting Autoriteit Financiële Markten, the **AFM**) on 27 October 2026 and available as of today (the **Prospectus**). The Prospectus has been published and made available at no cost through the website of the Company (<https://newsroom.avantium.com/rights-offering-2026>) subject to securities law restrictions in certain jurisdictions. Potential investors should read the Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the Rights, the Offer Shares or the Additional Shares. The approval of the Prospectus by the AFM should not be understood as an endorsement of the quality of the Rights, the Offer Shares or the Additional Shares.

Avantium announces the launch of a fully committed and underwritten rights offering of €55 million

AMSTERDAM, 27 October 2026, 08:15 hrs CET – Avantium N.V. (the “Company”, “Avantium” or the “Group”) today announces the launch of a capital increase by means of a fully committed and underwritten rights offering, for an amount of €55.45 million. The Offering is intended to remedy Avantium’s working capital shortfall, fund the ramp-up and commercialization of the FDCA Flagship Plant, and support Avantium’s transition into an industrial and commercial company focused on FDCA and PEF production and YXY® Technology licensing.

- 4 for 3 rights offering of 33,608,956 ordinary shares at an Issue Price of €1.65 per Offer Share
- Irrevocable shareholder commitments and cornerstone investments of €13.41 million in total, including commitments from long-term shareholders INNLE Publiek-Private Product Structurer B.V. (PPPS), for the account and risk of the State of the Netherlands, represented by the Minister of Climate and Green Growth (minister van Klimaat en Groene Groei), Pieter Kooi Holding B.V., Navitas B.V. and a new investor, in total representing c. 24.2% of the Offering



avantium

- The balance of the Offering has been fully underwritten for an aggregate amount of c. €42.04 million (the “Underwriting”)
- The Issue Price represents a discount of 42.7% to the theoretical ex-rights price based on the closing price of €4.52 on Euronext Amsterdam on 26 October 2026
- Ex-rights Date: 28 October 2026
- Rights trading period: from 9:00 CET on 28 October 2026 to 17:36 CET on 6 November 2026
- Record Time: 17:40 CET on 29 October 2026
- Exercise Period: from 9:00 CET on 28 October 2026 to 17:45 CET on 10 November 2026

Tom van Aken, Chief Executive Officer of Avantium, commented: “Following the successful production of the first FDCA at our FDCA Flagship Plant, we are entering an exciting new phase. This achievement marks an important step in our transition into a company focused on the production and global commercialization of FDCA and PEF. We are now producing additional FDCA, completing qualification activities and preparing for the first commercial deliveries under existing offtake agreements, expected toward the end of 2026. The successful production of FDCA at commercial scale represents an important step in the validation of our proprietary YXY® Technology and supports our licensing strategy for future FDCA and PEF production facilities. We have secured 23 offtake agreements for material to be produced at our FDCA Flagship Plant and 17 capacity reservation agreements representing more than 150 kilotonnes of potential annual production capacity from future licensed facilities, while advancing licensing discussions with prospective partners around the world.

The fully committed and underwritten circa €55 million rights offering that we announce today is intended to support the ramp-up of our Flagship Plant, strengthen our commercial and licensing activities and provide the funding needed to execute our growth strategy. The Offering will also strengthen our balance sheet and address the Company’s identified funding requirements as we continue the transition towards commercial operations. Together with the proposed €20 million loan from the NOM (the Investment and Development Agency for the Northern Netherlands), which would provide the Company with additional financial headroom, the Offering forms an important part of our broader financing plan and supports our ambition to build a leading global business around FDCA, PEF and YXY® Technology. We are grateful for the continued support of our shareholders, public partners and other stakeholders. Their commitment reflects a shared belief in the potential of FDCA and PEF to transform the plastics industry. We welcome both existing and new investors who share our ambition to create substantial value by bringing renewable and circular materials to market.”

Key terms of the Offering

- 4 for 3 rights offering of 33,608,956 new ordinary shares (the “Offer Shares”) at the issue price of €1.65 per Offer Share (the “Issue Price”) (the “Rights Offering”), for an amount of €55.45 million of gross proceeds.
- The Issue Price represents a discount of 42.7% to the theoretical ex-rights price (“TERP”) of €2.88, based on the closing price of €4.52 on Euronext Amsterdam on 26 October 2026.



avantium

- Shareholders are being granted transferable subscription entitlements (the **"Rights"**) in the Rights Offering, which will entitle them to subscribe in cash, on an irreducible basis, for Offer Shares. In addition, holders of Rights will be entitled to subscribe, on a reducible basis, for an additional number of Offer Shares, at the Issue Price (the **"Excess Application"**).
- The Offer Shares that are issuable upon the exercise of Rights but that are not subscribed for during the Exercise Period (the **"Rump Shares"**) will be offered for sale at the Issue Price through (i) a public offering in the Netherlands and Belgium, and (ii) private placements to certain institutional investors in certain other eligible jurisdictions (the **"Rump Offering"**, and together with the Rights Offering, the **"Offering"**).
- Several existing long-term shareholders of Avantium (the **"Committed Shareholders"**) have irrevocably undertaken to exercise all or part of their Rights for an aggregate amount of €6.31 million, or c. 11.4% of the Offering (the **"Irrevocable Commitments"**). Of this amount, INNLPubliek-Private Product Structurer B.V. (PPPS), for the account and risk of the State of the Netherlands, represented by the Minister of Climate and Green Growth (minister van Klimaat en Groene Groei) has committed €6.06 million and Navitas B.V. has committed €0.25 million.
- In addition, five cornerstone investors (the **"Cornerstone Investors"**) have irrevocably undertaken to subscribe for Offer Shares (the **"Cornerstone Shares"**) for an aggregate amount of €7.1 million, or c. 12.8% of the Offering (the **"Cornerstone Commitment"**). These Cornerstone Investors include Pieter Kooi Holding B.V. for €5.0 million, other existing shareholders for €1.1 million and a new investor, being a private individual through its holding company, for €1.0 million. The Cornerstone Investors will satisfy the Cornerstone Commitments first by irrevocably exercising their Rights in the Rights Offering (to the extent such Cornerstone Investor is a shareholder) for a total amount of c. €4.7 million, and thereafter by subscribing for the balance of c. €2.4 million in the Rump Offering. If the Cornerstone Commitments cannot be satisfied in full through the Rights Offering and the Rump Offering, the Cornerstone Investors will subscribe for the remaining Cornerstone Shares in a separate placement (the **"Additional Placement"**).
- The balance of c. €42.04 million, or c. 75.8% of the Rights Offering, is underwritten, subject to customary conditions, by Invest-NL Capital N.V. (**"Invest-NL"**), ABN AMRO Bank N.V. (**"ABN AMRO"**), BNP PARIBAS (**"BNPP"**), and Stifel Europe Securities SAS (**"Stifel"**) (altogether the **"Underwriters"**). Invest-NL will take a first allocation of any unsubscribed shares up to c. €10.5 million. Any remaining unsubscribed shares will be allocated pro rata among ABN AMRO, BNP PARIBAS and Stifel (acting as Joint Global Coordinators) in accordance with their respective underwriting commitments, subject to the terms and conditions of the Underwriting Agreement.
- Shareholders approved all resolutions required for the Offering at the Extraordinary General Meeting held on 30 September 2026, including the approval of an increase in the Company's authorized share capital and the designation of the Management Board, subject to Supervisory Board approval, to issue ordinary shares and limit or exclude pre-emptive rights until the 2027 Annual General Meeting.
- ABN AMRO will act as the Subscription, Listing and Paying Agent for the Rights Offering.

Indicative timetable

- The record time for allocation of the Rights is set at 17:40 CET on 29 October 2026 (the “**Record Time**”). Holders of Rights wishing to subscribe for Offer Shares must exercise their Rights during the Exercise Period, running from 9:00 CET on 28 October 2026 through 17:45 CET on 10 November 2026.
- The Company expects that the Rights will be admitted to listing and trading on Euronext Amsterdam and Euronext Brussels and that trading will commence at 09:00 CET on 28 October 2026 and will end at 17:36 CET on 6 November 2026, barring unforeseen circumstances.
- The Rights will be traded under the symbol "AVTRI" and ISIN code NL0015074EO7.
- The Excess Application will be open from 9:00 CET on 28 October 2026 until 17:45 CET on 10 November 2026.
- Settlement is expected to take place on 13 November 2026.

Reasons for the Offering and Use of Proceeds

With the Offering Avantium aims to raise c. €55.45 million in gross proceeds. Net proceeds are expected to amount to c. €50.5 million after deduction of c. €5.0 million in expenses related to the Offering, including administrative and legal fees and fees and commissions payable to the Underwriters. Avantium expects the net proceeds to remedy the working capital shortfall and to fund its working capital requirements for at least 12 months following the date of the Prospectus, supporting the path to a cumulative Group-level EBITDA break-even point from December 2027 onwards, subject to the assumptions and risks set out in the Prospectus.

The Offering is intended to support Avantium's transition into a company focused on the production, commercialization and global deployment of FDCA and PEF. The Offering follows delays in the start-up and ramp-up of the FDCA Flagship Plant, which resulted in deferred product sales and licence income, additional operating costs and approximately €7 million of additional capital expenditure associated with the titanium weld remediation programme.

Assuming c. €50.5 million in net proceeds from the Offering, Avantium currently intends to use the net proceeds primarily to fund operating expenses and working capital requirements for its FDCA and PEF business, including the ramp-up of the FDCA Flagship Plant and investments in commercial, technology and engineering activities supporting the commercialization of FDCA and PEF, and the licensing of its YXY[®] Technology. The proceeds will also be used to fund general corporate expenses, support the execution of the Company's strategic portfolio review and fund financing costs and forecast capital expenditure.

Working capital position

As of the end of October 2026, the Group's cash balance is projected to be approximately €9 million, of which approximately €5 million is restricted as a cash buffer under the Company's debt financing facilities and outstanding guarantees. Based on its liquidity forecast for the 12 months following



avantium

the date of the Prospectus, the Company faces a working capital shortfall of approximately €33 million.

The projected cash inflows for the relevant period have been calculated exclusively on the basis of (i) anticipated €14 million revenues generated by the Group's R&D Solutions business unit, (ii) €9 million in projected product sales emanating from the FDCA Flagship Plant, and (iii) an expected €17 million in (pre-)licence income from five separate parties. The forecasted cash outflows for this period most significantly comprise: (a) €71 million working capital related to operating expenses of the Company, including the ramp-up of the FDCA Flagship Plant; and (b) €6 million in interest on loans.

To remedy the working capital shortfall of approximately €33 million, Avantium has launched the Offering to raise gross proceeds of c. €55.45 million and net proceeds of c. €50.5 million. The difference between the expected net proceeds and the working capital shortfall as well as any proceeds from the issuance of Additional Shares provide an additional buffer to support the Company's working capital position and funding requirements, including in the event that assumed revenues from the R&D Solutions business, product sales from the FDCA Flagship Plant and (pre-) license income are not realized in full or are realized later than anticipated.

The Group is highly confident that the Offering will be completed, as it is fully secured through the Shareholders Commitments, the Cornerstone Commitments and the Underwriting. If successfully completed, the Offering is expected to provide sufficient working capital for the 12 months following the date of the Prospectus and support the Company's objective of reaching a cumulative Group-level EBITDA break-even on a monthly basis from December 2027 onwards, after which the Group expects to fund its operations from its cash flows, subject to achieving its targeted monthly revenue of approximately €7.5 million.

NOM Loan

In addition to the Offering, on 23 October 2026 the Company signed a term sheet with the NOM (the Investment and Development Agency for the Northern Netherlands) for a proposed €20 million subordinated loan facility (the "**NOM Loan**"). The NOM acts as indirect representative of the Ministry of Economic Affairs and Climate Policy under the Budget Strategic Acquisition (BSA), which forms part of the Nij Begun program. Nij Begun is a long-term Dutch government and regional development program aimed at recovery and future prosperity, including strengthening the economy of Groningen and North Drenthe in the Netherlands.

Under the signed term sheet, the NOM Loan would be made available in four tranches of €5 million, linked to milestones under Avantium's Transition Plan (the "**Transition Plan**"). This Transition Plan is intended to create lasting regional and societal impact and to further develop Groningen as Avantium's centre of excellence for industrialization, licensing and innovation. Milestones include the creation of a principal head office in the city of Groningen, the establishment of a licensing and training centre with regional partners, and the creation of an innovation hub and research collaborations with regional knowledge institutions. In addition, the first tranche of the NOM Loan may not be drawn before 1 March 2027, and the disbursement of each tranche is further conditional on the Company's free available liquidity being not less than €10 million and not more than €30 million at the time of disbursement. The Company aims to implement the Transition Plan in a



avantium

Press release

manner that supports its cost reduction, restructuring and EBITDA objectives and such that it does not result in unreasonable and disproportionate additional operating and capital expenses. The Company therefore does not expect the milestones to materially affect its working capital position.

The closing of the NOM Loan is subject to the following material conditions: (i) the receipt of approvals from the Province of Groningen and the Ministry of Economic Affairs and Climate Policy, following the positive advice from the investment committee of the NOM issued on 23 October 2026, (ii) the successful completion of the Offering, (iii) satisfactory documentation for the definitive loan agreement and (iv) no material adverse change having occurred before the execution of the definitive loan agreement and before the disbursement of each tranche. Subject to these conditions, the parties intend to finalize the definitive loan documentation and complete the transaction before the end of 2026.

Terms of the Offering

Details of the Offering are set forth in the Prospectus that has been approved by the Netherlands Authority for the Financial Markets (the “**AFM**”) and has been published today on <https://newsroom.avantium.com/rights-offering-2026>.

Rights Offering ratio and Issue Price

4 for 3 Rights Offering of 33,608,956 Offer Shares at an Issue Price of €1.65 per Offer Share. The Issue Price represents a discount of 42.7% to the TERP of €2.88, based on the closing price of €4.52 on Euronext Amsterdam on 26 October 2026. The Issue Price represents a discount of 63.5% to the closing price of the shares on 26 October 2026.

Record Time, Exercise Period and Excess Application

Each ordinary share held on the Record Time will entitle its holder to one (1) Right. Eligible Persons (as defined in the Prospectus) holding Rights, will be entitled to subscribe in cash, on an irreducible basis, for 4 Offer Shares for every 3 Rights held and, via the Excess Application on a reducible basis, for an additional number of Offer Shares they wish to acquire, at the Issue Price, from 9:00 CET on 28 October 2026 until 17:45 CET on 10 November 2026 (the “**Exercise Period**”).

The last date and/or time before which notification of Rights exercise and Excess Application instructions must be given in order to be valid may be earlier, depending on the financial institution through which the Rights are held. Rights can only be exercised in multiples of the Subscription Ratio (as defined in the Prospectus). No fractions of Offer Shares will be issued. Except as otherwise set out in the Prospectus, once an Eligible Person has exercised his or her Rights, he or she may not revoke or modify that exercise. Any Rights that have not been validly exercised by the end of the Exercise Period will expire and can no longer be exercised.

Listing of and trading of the Rights

Trading in the Rights on Euronext Amsterdam and Euronext Brussels is expected to commence at 9:00 CET on 28 October 2026 and will continue until 17:36 CET on 6 November 2026, barring unforeseen circumstances. The Rights will be listed and traded on Euronext Amsterdam and Euronext Brussels under the symbol “AVTRI” and ISIN NL0015074EO7.



avantium

Rump Shares

After the Exercise Period has ended, the Offer Shares that were issuable upon the exercise of Rights but that have not been validly subscribed for during the Exercise Period (the “**Rump Shares**”) will be offered for sale at the Issue Price through (i) a public offering in the Netherlands and Belgium and (ii) private placements to certain institutional investors in certain other eligible jurisdictions, subject to the terms and conditions of the Underwriting Agreement and applicable securities laws. The subscription price of the Rump Shares will be equal to the Issue Price.

The allocation of the Rump Shares will be made as follows: (i) first, the Cornerstone Investors will receive their guaranteed allocation of Cornerstone Shares, which will be satisfied through the Rump Shares to the extent available and, if necessary, through Additional Shares (the “**Additional Shares**”); (ii) second, Eligible Persons who have validly submitted an Excess Application will receive a proportionate allocation of any remaining Rump Shares, subject to the discretion of the Company and the Joint Global Coordinators; and (iii) third, new investors who have validly subscribed for Rump Shares will receive an allocation of any remaining Rump Shares or Upsize Shares (as defined below), as applicable, subject to the discretion of the Company and the Joint Global Coordinators.

The Company and the Joint Global Coordinators may, at their sole discretion, determine the allocation of the Rump Shares among Eligible Persons and new investors and may give preference to certain new investors over Eligible Persons who have validly submitted an Excess Application. The Company may also, taking into account market conditions and the best interests of the Company and its shareholders, issue additional Ordinary Shares up to an amount of €5 million (the “**Upsize Shares**”) to investors who subscribed in the Rump Offering but whose subscriptions could not be allocated in full.

Risk Factors

The following is a summary of the key risks that, alone or in combination with other events or circumstances, could have a material adverse effect on Avantium’s business, financial condition, results of operations or prospects:

- The Group is in financial distress and faces a working capital shortfall for the next 12 months following the date of this Prospectus of approximately €33 million. If the Offering is unsuccessful, and the Group as a result does not rectify its working capital shortfall, it will likely become insolvent;
- Even if the Group is able to resolve its working capital shortfall, no assurance can be given that the Group will be able to continue as a going concern, as the Group may continue to face liquidity challenges;
- The Group has incurred losses and negative operating cash flow and has an accumulated deficit. The Group anticipates that it will continue to incur losses for the foreseeable future and the Group may never achieve or sustain profitability;
- No assurance can be given that the ramp-up of the FDCA Flagship Plant will be completed on schedule, within budget or at all, and if the ramp-up of the FDCA Flagship Plant takes longer than expected, the Group will face additional operational costs and there is no assurance that the Group will have sufficient funds available to fund such additional costs;



avantium

- The commercial success of the YXY® Technology depends on the market acceptance of FDCA, PEF and PEF products and the Group's ability to sell FDCA, PEF and licences to third parties in respect of the production, manufacturing and/or application of the YXY® Technology, which may only become clear after the FDCA Flagship Plant becomes operational;
- The YXY® Technology may not perform as expected at the planned scale at the FDCA Flagship Plant and FDCA produced at the FDCA Flagship Plant or PEF produced by third parties under Licence may not meet the required product quality standards, performance tests or specifications;
- The Group may not be able to repay and/or refinance the existing debt financing facilities in an aggregate amount of €111.0 million granted by the lenders to the Company for the FDCA Flagship Plant; and
- An increase in interest rates may increase the Group's financing costs and may adversely affect its business.

For a full overview of the key risks, please refer to the Prospectus.

Lock-up undertakings

The Company has agreed to a lock-up period of 180 calendar days following settlement of the Offering, subject to certain customary exceptions. During this period, the Company may not, without the prior written consent of the Underwriters, issue or dispose of additional shares or share-linked securities. The lock-up does not apply to the issuance of the Rights, the Offer Shares and any Additional Shares or Upsize Shares, or to the Company's existing equity incentive arrangements. The Underwriters may waive the lock-up restrictions at their discretion.

In addition, the Committed Shareholders and the Cornerstone Investors have also agreed to a lock-up period expiring 90 calendar days following the date of settlement of the Offering in respect of the shares acquired in connection with the Offering. The lock-up arrangements are subject to certain customary exceptions.

Dilution

Shareholders who transfer, or who do not or are not permitted to exercise any of their Rights granted under the Offering, will suffer a dilution of their proportionate ownership and voting rights of approximately 57.1% as a result of the issue of the Offer Shares. If the full Additional Placement is completed, shareholders will experience additional dilution as a result of the issue of Additional Shares to the Cornerstone Investors and the issue of any Upsize Shares. The maximum additional dilution resulting from the Additional Placement would be approximately 7.1%.

In addition, Shareholders may experience further dilution in the future if outstanding warrants issued in connection with the Company's debt financing facilities are exercised. Certain warrants are subject to anti-dilution protection in connection with the Offering and future equity issuances. For further details, reference is made to the Prospectus.

Advisors



avantium

Press release

ABN AMRO, in cooperation with ODDO BHF, BNPP and Stifel are acting as Joint Global Coordinators for the Offering.

ABN AMRO will act as the Subscription, Listing and Paying Agent for the Offering.

Point Partners B.V. is acting as advisor to the Company.

Underwriting arrangements

The Company has secured gross proceeds of c. €55.45 million from the Offering through: (i) the Shareholders Commitments, (ii) the Cornerstone Commitment, and (iii) the underwriting, on a firm commitment basis, of any Offer Shares not subscribed for pursuant to the Offering, in accordance with the terms of the Underwriting Agreement entered into with Invest-NL, ABN AMRO, BNP PARIBAS and Stifel (together, the “**Underwriters**”).

Under the underwriting arrangements, Invest-NL will take a first allocation of any unsubscribed shares up to c. €10.5 million. Any remaining unsubscribed shares will be allocated pro rata among ABN AMRO, BNP PARIBAS and Stifel in accordance with their respective underwriting commitments, subject to the terms and conditions of the Underwriting Agreement.

Indicative timetable

Subject to acceleration or extension of the timetable for, or withdrawal of the Offering, the timetable below sets forth certain expected key dates for the Offering.

Event	Time and Date
Launch of the Offering and publication of the Prospectus	27 October 2026
Ex-rights date and start of trading in the Rights commences on Euronext Amsterdam and Euronext Brussels	9:00 CET on 28 October 2026
Start of the Offering Period	9:00 CET on 28 October 2026
Start of the Exercise Period	9:00 CET on 28 October 2026
Record Time	17:40 CET on 29 October 2026
End of trading in the Rights on Euronext Amsterdam and Euronext Brussels	17:36 CET on 6 November 2026
End of the Exercise Period and Excess Application	17:45 CET on 10 November 2026
Start Rump Offering	After 17:45 CET on 10 November 2026
End of Rump Offering	Before 9:00 CET on 11 November 2026
Allotment and issue of the Offer Shares and publication of a press release by the Company announcing the results of the Offering	Before 9:00 CET on 11 November 2026
Settlement Date	13 November 2026
Listing of and start of trading in the Offer Shares on Euronext Amsterdam and Euronext Brussels	9:00 CET on 13 November 2026

Availability of the Prospectus

The Offering is being made only by means of the Prospectus, approved by, and filed with, the AFM on 27 October 2026 as competent authority under the Prospectus Regulation. The Prospectus has been notified to the Belgian Financial Services and Markets Authority for passporting in accordance with article 25 of the Prospectus Regulation. The Prospectus is available electronically, free of charge, via the website of the Company <https://newsroom.avantium.com/rights-offering-2026> and the AFM website (<https://www.afm.nl/nl-nl/sector/registers/meldingenregisters/goedgekeurde-prospectussen>), subject to securities law restrictions in certain jurisdictions.

Information for Retail Investors

The Company has made available a Frequently Asked Questions document, in the Dutch language, on the Company's website: <https://newsroom.avantium.com/rights-offering-2026>

Prospective investors should carefully read and review the entire Prospectus and should form their own views before making an investment decision with respect to the Rights, the Offer Shares and the Additional Shares. Furthermore, before making an investment decision with respect to the Rights, the Offer Shares and the Additional Shares, prospective investors should consult their own professional adviser and carefully review the risks associated with an investment in the Rights, the Offer Shares and the Additional Shares and consider such an investment decision in light of their personal circumstances.

Half-year 2026 results

The half-year 2026 press release containing the HY2026 financial statements was published on 30 September 2026 and is available on the website of the Company: <https://newsroom.avantium.com/avantium-publishes-half-year-2026-financial-statements-and-completes-worley-contractual-close-out-for-fdca-flagship-plant/>

Previous announcements

Subsequent to 30 June 2026, the Company achieved several important operational, financing and strategic milestones. On 19 August 2026 and 7 September 2026, respectively, the Company announced the successful completion of the commissioning of the oxidation unit and purification unit at its FDCA Flagship Plant in Delfzijl. The Company subsequently produced its first batch of FDCA, marking the transition of the plant from commissioning to operational start-up and product qualification. The focus is now on producing additional FDCA volumes, completing customer qualification activities and preparing for commercial sales toward the end of 2026.

During the period, the Company continued to build its position in the commercialization of PEF through several additional agreements, including a capacity reservation agreement with Sukano, a partnership with Sojitz Pla-Net for the Japanese market, and a capacity reservation agreement with Klöckner Pentaplast for food packaging applications.

On 29 September 2026, the Company reached a conditional agreement with its lenders to amend and restate the Debt Financing Facilities and to provide agreed waivers in respect of certain



avantium

covenant and reporting breaches. The effectiveness of these amendments and waivers remains subject to the satisfaction of the successful completion of the Company's €55 million equity raise.

On 30 September 2026, shareholders adopted all resolutions at the Extraordinary General Meeting, providing the approvals required to implement the Company's financing package and related transactions. On the same day, the Company announced the successful contractual close-out and settlement with Worley in relation to the construction of the FDCA Flagship Plant, providing certainty regarding the final project costs and formally concluding the construction phase of the project.

On 1 October 2026, the Company completed the spin-out of its Parana technology into Parana Materials, further sharpening its strategic focus on the commercialization and global deployment of FDCA and PEF.

About Avantium

Avantium is a pioneering commercial-stage company focused on renewable & circular polymer materials. Avantium develops and commercializes innovative technologies for the production of materials based on sustainable carbon feedstocks. The most advanced technology is the YXY[®] Technology that catalytically converts plant-based sugars into FDCA (furandicarboxylic acid), the key building block for the sustainable plastic PEF (polyethylene furanoate). PEF is known under the brand name releaf[®], an EU registered trademark of Avantium. Avantium has successfully demonstrated the YXY[®] Technology at its pilot plant in Geleen, the Netherlands, and has produced the first FDCA in its FDCA Flagship Plant, the world's first commercial plant for FDCA in Delfzijl, the Netherlands. Avantium works in partnership with like-minded companies around the globe to develop revolutionary renewable chemistry solutions from invention to commercial scale.

Avantium's shares are listed on Euronext Amsterdam and Euronext Brussels (symbol: AVTX). Avantium is incorporated in the Euronext Amsterdam SmallCap Index (AScX). Its offices and headquarters are in Amsterdam, the Netherlands.

This press release by Avantium N.V. contains information that qualifies as inside information within the meaning of section 7(1) of Regulation (EU) No 596/2014 on market abuse.

Forward-looking information / disclaimer

This press release may include forward-looking statements. Other than reported financial results and historical information, all statements included in this press release, including, without limitation, those regarding our financial position, business strategy and management plans and objectives for future operations, are forward-looking statements. These forward-looking statements are based on our current expectations and projections about future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond Avantium's ability to control or estimate precisely, such as future market conditions, the behaviour of other market participants and the actions of governmental regulators. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of



avantium

this press release and are subject to change without notice. Other than as required by applicable law or the applicable rules of any exchange on which our securities may be traded, we have no intention or obligation to update forward-looking statements.

Any securities mentioned herein are not and will not be registered under the U.S. Securities Act of 1933, as amended (the **Securities Act**), and may not be offered or sold in the United States absent registration or unless pursuant to an applicable exemption from the registration requirements of the Securities Act. The Company has no intention to register any part of the offering in the United States or make a public offering of securities in the United States.

For more information:

Caroline van Reedt Dortland, Director Communications
+31-20-5860110 / +31-613400179
mediarelations@avantium.com

Aarne Luten, Director Investor Relations
+31-625687714
ir@avantium.com

DISCLAIMER

These materials are not for release, distribution or publication, whether directly or indirectly and whether in whole or in part, in or into the United States, Australia or Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

These materials are for information purposes only and are not intended to constitute, and should not be construed as, an offer to sell or a solicitation of any offer to buy the securities of Avantium N.V. (the Company, and such securities, the Securities) in the United States, Canada, Australia or Japan or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction.

This announcement is not for publication or distribution, directly or indirectly, in or into the United States. This announcement is not an offer of securities for sale into the United States. The Securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States. No public offering of securities is being made in the United States.

The Company has not authorised any offer to the public of Securities in any Member State of the European Economic Area and the United Kingdom other than the Netherlands and Belgium. With respect to any Member State of the European Economic Area and the United Kingdom, other than the Netherlands and Belgium (each a **Relevant Member State**), no action has been undertaken or will be undertaken to make an offer to the public of Securities requiring publication of a prospectus in any Relevant Member State. As a result, the Securities may only be offered in Relevant Member States (i) to any legal entity which is a qualified investor as defined in section 2(e) of the Prospectus Regulation; or (ii) in any other circumstances falling within section 1(4) of the Prospectus Regulation. For the purpose of this paragraph, the expression "offer of securities to the public"



avantium

means the communication in any form and by any means of sufficient information on the terms of the offer and the Securities to be offered so as to enable the investor to decide to purchase or subscribe for the Securities and the expression "Prospectus Regulation" means Regulation (EU) 2017/1129 and includes any relevant delegated regulations.

No action has been taken by the Company that would permit an offer of Securities or the possession or distribution of these materials or any other offering or publicity material relating to such Securities in any jurisdiction where action for that purpose is required.

The release, publication or distribution of these materials in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which they are released, published or distributed, should inform themselves about, and observe, such restrictions.

These materials may include statements, including the Company's financial and operational medium-term objectives that are, or may be deemed to be, "forward-looking statements". These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Company's business, results of operations, financial position, liquidity, prospects, growth or strategies. Forward-looking statements speak only as of the date they are made.

Each of the Company, as well as the Underwriters, including Joint Global Coordinators and their respective affiliates expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statement contained in these materials whether as a result of new information, future developments or otherwise.

The Joint Global Coordinators are acting exclusively for the Company and no one else in connection with any offering of Securities. They will not regard any other person as their respective clients in relation to any offering of Securities and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients nor for providing advice in relation to any offering of Securities, the contents of these materials or any transaction, arrangement or other matter referred to herein. None of the Underwriters or any of their respective subsidiary undertakings, affiliates or any of their respective directors, officers, employees, advisers, agents, alliance partners or any other entity or person accepts any responsibility or liability whatsoever for, or makes any representation, warranty or undertaking, express or implied, as to the truth, accuracy, completeness or fairness of the information or opinions in these materials (or whether any information has been omitted from these materials) or any other information relating to the group, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of these materials or its contents or otherwise arising in connection therewith. Accordingly, the Underwriters disclaim, to the fullest extent permitted by applicable law, all and any liability, whether arising in tort or contract or that they might otherwise be found to have in respect of these materials and/or any such statement.



avantium

This announcement does not constitute a prospectus. An offer to acquire Securities pursuant to the proposed offering will be made, and any investor should make his investment, solely on the basis of information that will be contained in the prospectus to be made generally available in the Netherlands and Belgium in connection with such offering. When made generally available, copies of the prospectus may be obtained at no cost from the Company or through the website of the Company.

In connection with the Offering, each of the Underwriters and any of their affiliates, may take up a portion of the Securities in the Offering as a principal position and, in that capacity, may retain, purchase, sell, offer to sell for its own account such Securities and other securities of the Company or related investments in connection with the Offering or otherwise. In addition, each of the Joint Global Coordinators and any of their affiliates may enter into financing arrangements (including swaps or contracts for differences) with investors in connection with which each of the Joint Global Coordinators and any of their affiliates may from time to time acquire, hold or dispose of Securities. None of the Joint Global Coordinators or their affiliates intends to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (MiFID II); (b) sections 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the **MiFID II Product Governance Requirements**), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Securities subject to the Offering have been subject to a product approval process, which has determined that such Securities are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the **Target Market Assessment**).

Notwithstanding the Target Market Assessment, "distributors" (for the purposes of the MiFID II Product Governance Requirements) should note that: the price of the Securities may decline and investors could lose all or part of their investment; the Securities offer no guaranteed income and no capital protection; and an investment in the Securities is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Offering.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Securities.



avantium

Press release

Each distributor is responsible for undertaking its own target market assessment in respect of the Securities and determining appropriate distribution channels.